ASCO21: targeted radiotherapy for previously treated metastatic castration-resistant prostate cancer

Written by Ryan Gilroy (Future Science Group)

mCRPC

Targeted radiotherapy lutetium-labeled PSMA-617 (177Lu PSMA-617), significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The study will be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting (4–8 June 2021) by researchers from Sloan Kettering Cancer Center (NY, USA). Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed in approximately 80% of patients with prostate cancer, including in metastatic disease making PSMA an attractive therapeutic target. 177Lu PSMA-617 is a radioactive compound that binds to prostate cancer...

To view this content, please register now for access

It's completely free